Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 5.1% – Should You Sell?

Ascendis Pharma A/S (NASDAQ:ASND) traded down 5.1% during trading on Thursday . The stock traded as low as $126.38 and last traded at $127.98. 108,859 shares traded hands during trading, a decline of 74% from the average session volume of 416,135 shares. The stock had previously closed at $134.87.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. TD Cowen dropped their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Oppenheimer decreased their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Stock Performance

The company has a market cap of $7.78 billion, a price-to-earnings ratio of -15.86 and a beta of 0.65. The company’s 50 day moving average price is $133.13 and its 200 day moving average price is $133.50.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its holdings in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Ascendis Pharma A/S by 42.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $945,000 after buying an additional 2,048 shares during the period. Simplify Asset Management Inc. acquired a new stake in Ascendis Pharma A/S during the second quarter valued at approximately $1,211,000. Evolutionary Tree Capital Management LLC grew its position in Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock valued at $3,391,000 after acquiring an additional 11,223 shares during the period. Finally, Profund Advisors LLC lifted its holdings in Ascendis Pharma A/S by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 85 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.